It was with great interest that we read the article by Jonas et al1 on intravitreal injection of triamcinolone fordiffuse diabetic macular edema. The authors are to be congratulated for bringingattention to this management option for a disease that currently has no effectivetreatment. There are, however, certain issues in the study that deserve comment.
The authors make no mention of their statistical method and includeonly means and standard deviations. To compare preinjection and postinjectionresults, did they use a polled t test (with bothgroups lumped together) or a paired t test (withindividuals measured)? While we do not question the statistically significantimprovement in visual acuity, it must be emphasized that the change is lessthan 2 Snellen lines. Furthermore, the visual acuities at 2 and 6 weeks areidentical but with very different P values, and theerror was higher at 6 weeks. Why is 0.13 ± 0.10 not significant at2 weeks but 0.13 ± 0.11 significant (with fewer number of eyes) at6 weeks?
Kuhn F, Barker D. Intravitreal Injection of Triamcinolone Acetonide for Diabetic MacularEdema. Arch Ophthalmol. 2004;122(7):1082–1083. doi:10.1001/archopht.122.7.1082-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: